COMMUNIQUÉS West-GlobeNewswire

Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
28/05/2026
SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) today announced that Vuong Trieu, Chief Executive Officer, will present the [...]
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
28/05/2026
ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, [...]
NewGen Executes Share Purchase Agreement and Obtains Exclusive APAC Agency Rights with K25.ai, an AI-Powered Prediction Market Led by Industry Veteran Andy Cheung
28/05/2026
NewGen executes Share Purchase Agreement to acquire an initial 2% equity interest in K25.ai, with the right to invest up to 10% in total NewGen also executes Exclusive Agency Agreement with K25.ai, appointing NewGen as [...]
Celcuity To Participate in Upcoming Investor Conferences
28/05/2026
MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, [...]
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
28/05/2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a [...]
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
28/05/2026
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare [...]
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
28/05/2026
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, [...]
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
28/05/2026
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (" [...]
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
28/05/2026
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
FOXO TECHNOLOGIES, INC., FORMS STRATEGIC PARTNERSHIP WITH LONGEVITYFP TECHNOLOGIES, LLC. TO COMMERCIALIZE FOXO’S EPIGENETICS TECHNOLOGY
28/05/2026
WEST PALM BEACH, FL and MINNETONKA, MN, May 28, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”) and LongevityFP Technologies, LLC. (“LFP”) today jointly announced a strategic partnership to [...]
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
28/05/2026
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
28/05/2026
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide [...]
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
28/05/2026
Repairon Announces Publication of Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon [...]
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
28/05/2026
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumours US trial (OCTOPOD-IP) is exploring [...]
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
28/05/2026
Study to evaluate the safety and exploratory efficacy of SYN002 in recipients of human cytomegalovirus (CMV) positive donor kidneys, and to monitor for viral reactivation over the six months following transplantation [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
28/05/2026
Freising, Germany, May 28, 2026 (GLOBE NEWSWIRE) -- XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 [...]
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]

Pages